The DOI matches its Crossref record; 24 of the 27 references it cites were found in a registry or an index.
The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration
Abstract
Neovascular age-related macular degeneration (nvAMD) is a chronic, progressive disease of the central retina, and its prevalence is expected to rise with the ageing population. Using a bottom-up approach based on retrospective data, this cross-sectional study estimated average annual direct costs of nvAMD to be £4,047, and average annual indirect costs to be £449. An attempt to measure intangible costs through willingness-to-pay yielded a lower response rate and estimated intangible costs to be 11.5% of monthly income. Direct costs were significantly higher for male participants, for those who have mild or moderate visual impairment in both eyes, and for those who have been diagnosed for a shorter time. The findings of this study suggest that the availability of early diagnosis, effective treatment, support services, and sustained research into the management of nvAMD may reduce the burden of visual impairment caused by nvAMD to affected individuals and the state.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In terms of informal care costs, they were estimated in two studies [34, 39], ranging from $2,508 to $6,634 per patient per annum.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [39]
In the citing paper
“The most frequent resources accounted for within direct non-medical costs were formal care [34, 38–43, 45] and assistive technologies [34, 37–39, 41–43, 45], followed by transportation [34, 37–39, 42, 45] and subsidies [40–43] (Table 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [39]
In the citing paper
“While annual direct non-medical costs were uniformly lower than direct medical costs in three studies [34, 39, 40] reporting both types of costs, they were higher in other cases [37, 41–43, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [39]
In the citing paper
“Nine studies [34, 37–43, 45] reported direct non-medical costs per patient per annum, ranging from $688 to $15,418 (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [39]
In the citing paper
“Annual productivity loss in patients ranged from $23 to $1,006 [34, 39].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [39]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1941) · Research in International Economics by Federal Agencies · doi:10.7312/schw92626-009 · Cited by 4,682
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Risk factors for age-related macular degeneration
Smith, W., Assink, J., Klein, R., Mitchell, P., Klaver, C. C. W., Klein, B. E. K., Hofman, A., Jensen, S., Wang, J. J., & de Jong, P. T. V. M. (2001) · Ophthalmology · doi:10.1016/s0161-6420(00)00580-7 · Cited by 1,071
Economic Preferences or Attitude Expressions?: An Analysis of Dollar Responses to Public Issues
Kahneman, D., Ritov, I., Schkade, D., Sherman, S. J., & Varian, H. R. (1999) · Elicitation of Preferences · doi:10.1007/978-94-017-1406-8_8 · Cited by 509
Economic Preferences or Attitude Expressions?: An Analysis of Dollar Responses to Public Issues
Kahneman, D., Ritov, I., & Schkade, D. (1999) · Journal of Risk and Uncertainty · doi:10.1023/a:1007835629236 · Cited by 422
Risk Factors for Age-related Macular Degeneration
Evans, J. R. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(00)00023-9 · Cited by 339
The determinants of participation in activities of daily living in people with impaired vision
Lamoureux, E. L., Hassell, J. B., & Keeffe, J. E. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.08.003 · Cited by 246
VERTEPORFIN ROUNDTABLE 2000 AND 2001 PARTICIPANTS, T. O. A.-R. M. D. W. P. T. (. S. G. P. I. (2002) · Retina · doi:10.1097/00006982-200202000-00003 · Cited by 246
Owen, C. G. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.3.312 · Cited by 210
Vogel, R. J. (1983) · Social Science & Medicine · doi:10.1016/0277-9536(83)90205-8 · Cited by 161
Research works printed but not linked: 4
- Curtis, L., Netten, A.: Unit costs of health and social care 2006. Personal Social Services Research Unit, Canterbury (2006)
- AA Motoring Trust: The cost of motoring—2006. AA Motoring Trust, London (2006)
- National Institute for Clinical Excellence (NICE): Technology appraisal 68: guidance on the use of photodynamic therapy for age-related macular degeneration. NICE, London (2003)
- Romans, F.: The transition of women and men from work to retirement. No. 97/2007. Eurostat, Luxembourg (2007)
Cited by
Extra costs of living with a disability: A review and agenda for research
Mitra, S., Palmer, M., Kim, H., Mont, D., & Groce, N. (2017) · Disability and Health Journal · doi:10.1016/j.dhjo.2017.04.007 · Cited by 386
The economics of vision impairment and its leading causes: A systematic review
Marques, A. P., Ramke, J., Cairns, J., Butt, T., Zhang, J. H., Jones, I., Jovic, M., Nandakumar, A., Faal, H., Taylor, H., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101354 · Cited by 137
Age-Related Macular Degeneration: Insights into Inflammatory Genes
Cascella, R., Ragazzo, M., Strafella, C., Missiroli, F., Borgiani, P., Angelucci, F., Marsella, L., Cusumano, A., Novelli, G., Ricci, F., et al. (2014) · Journal of Ophthalmology · doi:10.1155/2014/582842 · Cited by 78
“Consequently AMD substantially impacts the lifestyle of patients by compromising everyday activities, such as reading and driving [3–5].”
BackgroundSOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES
Brown, M. M., Brown, G. C., Lieske, H. B., Tran, I., Turpcu, A., & Colman, S. S. (2015) · Retina · doi:10.1097/iae.0000000000000717 · Cited by 61
Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Bocci, V. A., Zanardia, I., Valacchi, G., Borrelli, E., & Travagli, V. (2015) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x1502151209114642 · Cited by 61
Metadata
- Authors
- Ke, K. M.
- Venue
- The European Journal of Health Economics
- Published
- 2009-11-21
- Volume
- 11
- Issue
- 6
- Pages
- 525-531
- ISSN
- 1439-3972 (ISSN-L)
- 1618-7598
- 1618-7601
- OpenAlex
- W2104216015
- Cited by
- 25
- References
- 27
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 3 · 2022: 1 · 2021: 2 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 1 · 2012: 2
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- The European Journal of Health Economics (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- neovascular age-related macular degeneration, visual impairment, direct costs, indirect costs, intangible costs, willingness to pay, economic burden, gender differences, disease duration, early diagnosis
- MeSH terms
- Aged, Aged, 80 and over, Analysis of Variance, Blindness, Cross-Sectional Studies, Health Expenditures, Female, Humans, Macular Degeneration, Male, Middle Aged, Neovascularization, Pathologic, Northern Ireland, Regression Analysis, Retrospective Studies, Confidence Intervals, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1007/s10198-009-0207-9
- The paper
- Ke, K. M. (2010). The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration. The European Journal of Health Economics. https://doi.org/10.1007/s10198-009-0207-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.